Heart Imaging Study During Cancer Drug Treatment
Part of Heart & circulation, Injuries & trauma clinical trials.
This study uses heart imaging scans and blood tests to check if a common cancer drug (anthracycline) is affecting your heart during treatment. Early detection might help doctors protect your heart health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You need to receive at least four doses of an anthracycline (a type of chemotherapy drug) as part of your cancer treatment
- You have never received anthracycline chemotherapy before
- You have not received other heart-damaging drugs in the past 6 months (like HER2 inhibitors, immunotherapy drugs, or high-dose cyclophosphamide)
- You don't have a pacemaker or other metal implants that would prevent you from having heart imaging scans
- You have no prior heart radiation to the chest area before starting this treatment
- You are able to understand and give consent to participate in this study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses detailed heart imaging (a special MRI scan) to see how chemotherapy may have affected your heart and to predict who could develop heart failure later. If you qualify, it may help your care team better monitor your heart health over time.
This trial uses a special scoring system (ML Score) to predict if you might develop heart problems while receiving anthracycline chemotherapy or HER2-targeted therapies. It helps doctors decide on the best heart monitoring plan before starting treatment.
This study watches how chemotherapy and HER2-targeted drugs affect your heart during early-stage breast cancer treatment. Researchers use heart scans to catch any changes early and understand how to protect heart health.
This study looks at whether a simple blood test can spot early signs of heart damage from certain breast cancer treatments (anthracycline chemo or anti-HER2 drugs). The goal is to protect your heart while you get the cancer treatment you need.
This trial follows people with metastatic HER2-positive breast cancer who are at higher risk for heart damage while on HER2-targeted therapy. Some participants are randomly assigned to different monitoring/heart-protection approaches to see what best helps keep the heart safe.
This trial checks how anthracycline chemotherapy affects the heart and blood vessels in children and teens who had cancer. It aims to help doctors better understand long-term heart risks and follow-up care.
Hear when a new Cardiotoxicity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.